Systemic Erythropoietin Injection in Patients Having Optic Atrophy

Status Completed

Clinical Trial Summary

The purpose of this treatment trial is to study the effect of systemic erythropoietin in patients having optic atrophy.

Clinical Trial Description

The purpose of this treatment trial is to study the effect of systemic erythropoietin in patients having optic atrophy. The intervention is systemic erythropoietin injections (eprax 10000 IU subcutaneous twice daily for three days). Follow up after one month and three months by recording visual acuity and electro physiological studies. ;

Study Design

Related Conditions & MeSH terms

Clinical Trial Details

NCT number	NCT04680143
Study type	Interventional
Source	Alexandria University
Contact
Status	Completed
Phase	Phase 1/Phase 2
Start date	September 1, 2020
Completion date	March 30, 2021

View Details

See also
Status	Clinical Trial	Phase
Recruiting	`NCT01834079` - Study the Safety and Efficacy of Bone Marrow Derived Autologous Cells for the Treatment of Optic Nerve Disease	Phase 1/Phase 2
Completed	`NCT04594590` - Natural History Study of SLC25A46 Mutation-related Mitochondriopathy
Completed	`NCT04580979` - Natural History Study of FDXR Mutation-related Mitochondriopathy
Recruiting	`NCT03011541` - Stem Cell Ophthalmology Treatment Study II	N/A
Completed	`NCT01064505` - Safety Study of a Single IVT Injection of QPI-1007 in Chronic Optic Nerve Atrophy and Recent Onset NAION Patients	Phase 1
Recruiting	`NCT05147701` - Safety of Cultured Allogeneic Adult Umbilical Cord Derived Mesenchymal Stem Cells for Eye Diseases	Phase 1
Not yet recruiting	`NCT02882477` - Treatment of Wolfram Syndrome Type 2 With the Chelator Deferiprone and Incretin Based Therapy	Phase 2/Phase 3
Completed	`NCT04723160` - Computer Aided Diagnosis of Multiple Eye Fundus Diseases From Color Fundus Photograph